German pharma adds drugs for rare tumors, expands U.S. footprint via $3.9B acquisition

New binding domains, target combinations and molecule structures define the VEGF multispecifics to be presented at AACR 2025

Plus: The week’s gainers and decliners after data

Western biopharmas signed more deals for bispecifics than ADCs with China biotechs last year

Plus Radiance gets ROR1 ADC from Cspc, Astrazeneca buys Fibrogen’s China subsidiary and more

How the once-dominant cancer company has overhauled its strategy for long-term growth

70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas

In BioCentury’s Finance Report, two more companies plan Hong Kong listings; Disc Medicine, Arctic raise cash